Skip to main content

Table 4 Collected time-killing assay results of various combinations of ML and HL with antibacterial agents at 24 h incubation against a clinical MRSA144 strain

From: In vitro synergism of magnolol and honokiol in combination with antibacterial agents against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA)

Combinationa

Mascb

â–³LC24(Int)c

HL + ETM

ETM

2.25 ± 0.12(Syn)*

HL + LEV

HL

2.09 ± 0.09(Syn)*

ML + ETM

ETM

2.08 ± 0.1(Syn)*

HL + AMK

AMK(~ML)

2.05 ± 0.07(Syn)*

HL + FOS

FOS

2.04 ± 0.03(Syn)

HL + GEN

HL

2.02 ± 0.01(Syn)

ML + AMK

AMK(~ML)

2.02 ± 0.02(Syn)

ML + FOS

FOS(~ML)

2.00 ± 0.01(Add)

ML + LEV

LEV(=ML)

1.64 ± 0.04(Add)

ML + CIP

CIP

1.24 ± 0.05(Add)

ML + GEN

GEN

1.24 ± 0.03(Add)

HL + CIP

HL

1.06 ± 0.04(Add)

  1. aSAL Salvianolate, AMP Ampicillin, CAZ Ceftazidime, CFZ Cefazolin, CPS Cefoperazone-sulbactam, PTZ Piperacillin-tazobactam, AMK Amikacin, CLI Clindamycin, ERY Erythromycin, FOS Fosfomycin, LEV Levofloxacin
  2. bMasc Most active single drug
  3. c△LC 24 △Log10CFU/mL at 24 h, Int Interaction, Syn Synergy (△LC24 ≥ 2), Add Additivity (1 < △LC24 < 2), Ind Indifference (△LC24 = ±1). Data are expressed as the mean ± standard error. *p <0.05